"Dynamic range" of inferred phenotypic HIV drug resistance values in clinical practice.

<h4>Background</h4>'Virtual' or inferred phenotypes (vPhenotypes) are commonly used to assess resistance to antiretroviral agents in patients failing therapy. In this study, we provide a clinical context for understanding vPhenotype values.<h4>Methods</h4>All HIV-in...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Luke C Swenson, Graham Pollock, Brian Wynhoven, Theresa Mo, Winnie Dong, Robert S Hogg, Julio S G Montaner, P Richard Harrigan
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2011
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/3059e66ab4d6446b86b08340fd903ccc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3059e66ab4d6446b86b08340fd903ccc
record_format	dspace
spelling	oai:doaj.org-article:3059e66ab4d6446b86b08340fd903ccc2021-11-18T06:58:18Z"Dynamic range" of inferred phenotypic HIV drug resistance values in clinical practice.1932-620310.1371/journal.pone.0017402https://doaj.org/article/3059e66ab4d6446b86b08340fd903ccc2011-02-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/21390218/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>'Virtual' or inferred phenotypes (vPhenotypes) are commonly used to assess resistance to antiretroviral agents in patients failing therapy. In this study, we provide a clinical context for understanding vPhenotype values.<h4>Methods</h4>All HIV-infected persons enrolled in the British Columbia Drug Treatment Program with a baseline plasma viral load (pVL) and follow-up genotypic resistance and pVL results were included up to October 29, 2008 (N = 5,277). Change from baseline pVL was determined as a function of Virco vPhenotype, and the "dynamic range" (defined here by the 10th and 90th percentiles for fold-change in IC₅₀ amongst all patients) was estimated from the distribution of vPhenotye fold-changes across the cohort.<h4>Results</h4>The distribution of vPhenotypes from a large cohort of HIV patients who have failed therapy are presented for all available antiretroviral agents. A maximum change in IC₅₀ of at least 13-fold was observed for all drugs. The dideoxy drugs, tenofovir and most PIs exhibited small "dynamic ranges" with values of <4-fold change observed in > 99% of samples. In contrast, zidovudine, lamivudine, emtricitabine and the non-nucleoside reverse transcriptase inihibitors (excluding etravirine) had large dynamic ranges.<h4>Conclusion</h4>We describe the populational distribution of vPhenotypes such that vPhenotype results can be interpreted relative to other patients in a drug-specific manner.Luke C SwensonGraham PollockBrian WynhovenTheresa MoWinnie DongRobert S HoggJulio S G MontanerP Richard HarriganPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 6, Iss 2, p e17402 (2011)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Luke C Swenson Graham Pollock Brian Wynhoven Theresa Mo Winnie Dong Robert S Hogg Julio S G Montaner P Richard Harrigan "Dynamic range" of inferred phenotypic HIV drug resistance values in clinical practice.
description	<h4>Background</h4>'Virtual' or inferred phenotypes (vPhenotypes) are commonly used to assess resistance to antiretroviral agents in patients failing therapy. In this study, we provide a clinical context for understanding vPhenotype values.<h4>Methods</h4>All HIV-infected persons enrolled in the British Columbia Drug Treatment Program with a baseline plasma viral load (pVL) and follow-up genotypic resistance and pVL results were included up to October 29, 2008 (N = 5,277). Change from baseline pVL was determined as a function of Virco vPhenotype, and the "dynamic range" (defined here by the 10th and 90th percentiles for fold-change in IC₅₀ amongst all patients) was estimated from the distribution of vPhenotye fold-changes across the cohort.<h4>Results</h4>The distribution of vPhenotypes from a large cohort of HIV patients who have failed therapy are presented for all available antiretroviral agents. A maximum change in IC₅₀ of at least 13-fold was observed for all drugs. The dideoxy drugs, tenofovir and most PIs exhibited small "dynamic ranges" with values of <4-fold change observed in > 99% of samples. In contrast, zidovudine, lamivudine, emtricitabine and the non-nucleoside reverse transcriptase inihibitors (excluding etravirine) had large dynamic ranges.<h4>Conclusion</h4>We describe the populational distribution of vPhenotypes such that vPhenotype results can be interpreted relative to other patients in a drug-specific manner.
format	article
author	Luke C Swenson Graham Pollock Brian Wynhoven Theresa Mo Winnie Dong Robert S Hogg Julio S G Montaner P Richard Harrigan
author_facet	Luke C Swenson Graham Pollock Brian Wynhoven Theresa Mo Winnie Dong Robert S Hogg Julio S G Montaner P Richard Harrigan
author_sort	Luke C Swenson
title	"Dynamic range" of inferred phenotypic HIV drug resistance values in clinical practice.
title_short	"Dynamic range" of inferred phenotypic HIV drug resistance values in clinical practice.
title_full	"Dynamic range" of inferred phenotypic HIV drug resistance values in clinical practice.
title_fullStr	"Dynamic range" of inferred phenotypic HIV drug resistance values in clinical practice.
title_full_unstemmed	"Dynamic range" of inferred phenotypic HIV drug resistance values in clinical practice.
title_sort	"dynamic range" of inferred phenotypic hiv drug resistance values in clinical practice.
publisher	Public Library of Science (PLoS)
publishDate	2011
url	https://doaj.org/article/3059e66ab4d6446b86b08340fd903ccc
work_keys_str_mv	AT lukecswenson dynamicrangeofinferredphenotypichivdrugresistancevaluesinclinicalpractice AT grahampollock dynamicrangeofinferredphenotypichivdrugresistancevaluesinclinicalpractice AT brianwynhoven dynamicrangeofinferredphenotypichivdrugresistancevaluesinclinicalpractice AT theresamo dynamicrangeofinferredphenotypichivdrugresistancevaluesinclinicalpractice AT winniedong dynamicrangeofinferredphenotypichivdrugresistancevaluesinclinicalpractice AT robertshogg dynamicrangeofinferredphenotypichivdrugresistancevaluesinclinicalpractice AT juliosgmontaner dynamicrangeofinferredphenotypichivdrugresistancevaluesinclinicalpractice AT prichardharrigan dynamicrangeofinferredphenotypichivdrugresistancevaluesinclinicalpractice
_version_	1718424092186509312

"Dynamic range" of inferred phenotypic HIV drug resistance values in clinical practice.

Ejemplares similares